乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Oncology/Hematology >

Lymphoma

News, opinions and meeting coverage in oncology/hematology.

<乌鸦传媒>Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T

But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question

A photo of the packaging and blisterpack of Carvedilol tablets

<乌鸦传媒>Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors

While safe, the results do not support use of the drug in anthracycline-exposed survivors

<乌鸦传媒>Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients

Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study

<乌鸦传媒>Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma

Study results show impressive efficacy, favorable safety profile in the second line

<乌鸦传媒>Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL

Approach could allow for a response-adapted reduction of CHOP

<乌鸦传媒>Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma

Our panel of experts discuss 3-year findings from the phase II ELARA study

<乌鸦传媒>Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years

Bispecific antibody also shows high response rates in frontline setting

<乌鸦传媒>Positive Results for Odronextamab in Relapsed/Refractory DLBCL

But experts aren't sure where it would fit in with currently approved bispecifics

A computer rendering of lymphoma cells in the blood

<乌鸦传媒>JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma

Phase II findings on golidocitinib will form the basis of an accelerated approval application

ASH over a photo of San Diego Convention Center.

<乌鸦传媒>Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma

Will results revive ibrutinib role in MCL following withdrawal of accelerated approval?

ASH over a photo of San Diego Convention Center.

<乌鸦传媒>ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission

Better 2-year PFS, OS, but not applicable to primary refractory disease

A computer rendering of non-Hodgkin lymphoma cells in the blood flow

<乌鸦传媒>Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL

Patients with treatment-sensitive disease may benefit most from continued treatment, says expert

A photo of a young female physician looking at MRI scans of her patient鈥檚 brain.

<乌鸦传媒>Charting the Course: From Young Adult Leukemia Patient to Oncologist

My experience shaped how I care for patients today

YIR FOLLICULAR LYMPHOMA over a microscope image of follicular lymphoma.

<乌鸦传媒>Year in Review: Follicular Lymphoma

A promising year for bispecific antibodies

A scanning electron microscope image of CAR-T cells attacking a cancer cell.

<乌鸦传媒>FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy

Applies to all approved therapies, but benefits still outweigh risks, agency says

A photo of a spilled bottle of Eliquis tablets.

<乌鸦传媒>Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL

However, it may benefit children at increased risk of thrombosis

FDA ADCOMM pralatrexate (Folotyn), belinostat (Beleodaq) over a computer rendering of lymphoma cells in the blood flow.

<乌鸦传媒>FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent'

No easy answers for two drugs for rare lymphoma on long cruise with accelerated approval

A photo of the vial and packaging of Aliqopa.

<乌鸦传媒>Lymphoma Drug Copanlisib to Be Pulled From U.S. Market

Failed confirmatory trial takes down another PI3K inhibitor

Onco Break over a computer rendering of a cancer cell.

<乌鸦传媒>Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh

News, features, and commentary about cancer-related issues

Onco Break over a computer rendering of a cancer cell.

<乌鸦传媒>Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening

News, features, and commentary about cancer-related issues

A photo of a surgeon performing radiofrequency ablation

<乌鸦传媒>Weight-Loss Surgery Tied to Lower Blood Cancer Risk in Women

Consider surgery for primary prevention in people with obesity, researchers suggest

SOHO over a photo of George R. Brown Convention Center in Houston, Texas.

<乌鸦传媒>High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody

Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab

SOHO meeting

<乌鸦传媒>Study Questions Value of Interim PET Imaging to Guide Frontline Hodgkin Treatment

One of 40 patients changed treatment but all remained on brentuximab regardless of scan results

A close up photo of a nurse taping the intravenous line to her male patient鈥檚 wrist during chemotherapy.

<乌鸦传媒>Standard Lymphoma Therapies Tied to Higher Risk for New Malignancies

Increased risk for non-melanoma skin cancer, MDS, AML versus the general population

A photo of a female nurse prepping her senior male patient for chemotherapy.

<乌鸦传媒>Adcetris Plus Chemo Effective in HIV-Related Hodgkin Lymphoma

Researchers call study "practice changing," although outside experts urge caution

A photo of a vial of Keytruda over a high magnification micrograph of primary mediastinal large B-cell lymphoma

<乌鸦传媒>Anti-PD-1 Alone Produces Durable Responses in Relapsed/Refractory PMBCL

More than 80% of responding patients remained in response at 4 years

A photo of bottles of Jaypirca 100 mg and 50 mg.

<乌鸦传媒>Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL

73% of patients with prior exposure to covalent BTK inhibitors responded

Onco Break over a computer rendering of a cancer cell.

<乌鸦传媒>WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer

News, features, and commentary about cancer-related issues

A photo of a man鈥檚 torso affected by erythroderma.

<乌鸦传媒>Why Did Older Man Develop Itchy, Full-Body Rash?

Here's how the medical team diagnosed and treated the rare inflammatory skin disorder

FDA APPROVED glofitamab (Columvi) over a computer rendering of antibodies attacking cancer cells.

<乌鸦传媒>New Bispecific Antibody Approved for Tough-to-Treat Lymphoma

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

Onco Break over a computer rendering of a cancer cell.

<乌鸦传媒>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages

News, features, and commentary about cancer-related issues

A photo of a sad looking mature woman with her hands on her head.

<乌鸦传媒>Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis

Patients with depression alone had the worst overall survival

A photo of a box of Breyanzi over a computer rendering of CAR-T cells attacking a cancer cell

<乌鸦传媒>CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial

All patients had progressed on BTK inhibitors and most had failed venetoclax

ASCO over a photo of McCormick place in Chicago, IL.

<乌鸦传媒>Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission

PET-negative patients after chemoimmunotherapy fared well with observation alone

ASCO over a photo of McCormick place in Chicago, IL.

<乌鸦传媒>Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma

The CAR T-cell therapy led to significantly longer overall survival

ASCO over a photo of McCormick place in Chicago, IL.

<乌鸦传媒>Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma

SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease

A photo of Hank Green

<乌鸦传媒>What to Know About Hank Green's Hodgkin's Lymphoma Diagnosis

Hodgkin's is one of the more rare lymphomas, but tends to be very treatable

A photo of a medical technician preparing a hematopoietic stem cells bag

<乌鸦传媒>Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas

Results will likely "encourage a practice change," editorialists say

A photo of a blood sample laying on genetic testing results.

<乌鸦传媒>B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's

Findings may bolster interest in BTK inhibitors for autoimmune diseases

FDA APPROVED polatuzumab vedotin (Polivy) over a computer rendering of antibodies attacking a cancer cell.

<乌鸦传媒>Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL

Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS

2